Evidence map›Paper›PMID 40330903›Full record

ArticleMolecular therapy. Oncology2025

hsa-miR-5688 inhibits FOXC1-OCT4/SOX2 feedforward loop that drives chemoresistance in breast cancer stem cells.

Apratim Dutta, Sourio Chakraborty, Apoorva Bhattacharya, Udit Basak, Subhadip Pati, Sumon Mukherjee, Deblina Guha, Shruti Banerjee, Nibedita Ray Chaudhuri, Diptendra Sarkar and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Apratim DuttaCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Sourio ChakrabortyCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Apoorva BhattacharyaCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Udit BasakCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Subhadip PatiCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Sumon MukherjeeCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Deblina GuhaCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Shruti BanerjeeCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Nibedita Ray ChaudhuriUnified Academic Campus, Bose Institute, HCGJ+4X5, EN Block, Sector V, Bidhannagar, Kolkata, West Bengal 700091, India.
Diptendra SarkarDepartment of Surgery, IPGMER and SSKM Hospital, Kolkata 700020, India.
Kuladip JanaUnified Academic Campus, Bose Institute, HCGJ+4X5, EN Block, Sector V, Bidhannagar, Kolkata, West Bengal 700091, India.
Gaurisankar SaCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
Shubhra Ghosh DastidarUnified Academic Campus, Bose Institute, HCGJ+4X5, EN Block, Sector V, Bidhannagar, Kolkata, West Bengal 700091, India.
Tanya DasCentenary Building, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inherently chemotherapy-resistant breast cancer stem cells (CSCs) are responsible for tumor initiation, metastasis, and relapse. CSCs "acquire" more resistance and stemness upon chemotherapy, thereby making relapse-free survival extremely challenging. Here, we describe a novel role of FOXC1 in "acquired resistance" of breast CSCs during chemotherapy. Putative binding sites of pluripotency factors OCT4 and SOX2, but not NANOG, on FOXC1 promoter, were demonstrated by JASPAR and validated by a docking experiment. Significant decline in FOXC1 expression was noticed after OCT4 or SOX2 ablation in breast CSCs. Contrastingly, presence of putative FOXC1 binding sites on the promoters of stemness genes and drug-resistance marker ABCG2, along with downregulation of OCT4 and SOX2 in FOXC1-ablated CSCs, indicated the existence of a feedforward FOXC1-OCT4/SOX2 transactivation loop in CSCs. Chemotherapy-induced upregulation of FOXC1, stemness, as well as drug resistance in CSCs, and downregulation of the same by prior FOXC1-ablation in

Indexed as

acquired resistancebreast cancer stem cellschemotherapyFOXC1hsa-miR-5688MT: Regular Issuerecurrence

Identifiers

PMID40330903
PMCPMC12051596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.